Prof. Yingjian Liang 梁英健
Chief Physician, Professor
Department of Hepatobiliary and Pancreatic Surgery, Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Laparoscopic minimally invasive treatment for liver cancer, hepatic hemangioma, hepatic cysts, and hilar cholangiocarcinoma. Minimally invasive treatment for gallbladder and bile duct stones, and complex biliary diseases.
Dr. Liang holds a PhD and serves as Chief Physician and Master’s Supervisor. Since 2007, Dr. Liang has worked at the First Affiliated Hospital of Harbin Medical University, including a visiting scholar role at the New Jersey Cancer Institute (October 2011–January 2013). Dr. Liang holds grants from the National Natural Science Foundation and has published over 10 SCI articles, including first-author papers in Hepatology and Nature Communications.
Professional roles
- Member, Minimally Invasive Surgery Youth Committee, Surgical Branch of Chinese Medical Doctor Association
- Member, Hernia and Abdominal Wall Surgery Society, Youth Committee of Chinese Medical Doctor Association
- Member, Colon Cancer Liver Metastasis Society, China International Health Care Promotion Committee
- Member, Digital Medicine Clinical Surgery Professional Committee, Chinese Research Hospital Association
Name order: in Chinese the family name comes first (Liang Yingjian). Papers usually list the name as Yingjian Liang or Liang Y.
Selected publications
9 papers on PubMed matched by name and affiliation; 3 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Sci, 2026 (senior author): Mapping the Tissue Architecture and Endothelial-PEC Network in HAML Using Single-Cell and Spatial Transcriptomics. PubMed 42841778
- Nutr J, 2025 (senior author): Daily eating frequency, nighttime fasting duration, and the risk of non-alcoholic fatty liver disease: a cross-sectional study. PubMed 41024050
- Oncogenesis, 2020 (first author): lncRNA-SOX2OT promotes hepatocellular carcinoma invasion and metastasis through miR-122-5p-mediated activation of PKM2. PubMed 32467565
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion